Yonsei University College of Medicine, Department of Internal Medicine, Division of Endocrinology, Severance Hospital, Diabetes Center
Welcome,         Profile    Billing    Logout  
 4 Trials 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cha, Bong Yun
NCT03646292: Antidiabetic Drugs for Steatotic Liver Disease

Completed
4
51
RoW
Pioglitazone, Empagliflozin, Combination of pioglitazone and empagliflozin
Yonsei University
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Type 2 Diabetes, Digestive System Disease, Liver Diseases, Fatty Liver, Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-Alcoholic Fatty Liver Disease, Hypoglycemic Agents, Physiological Effects of Drugs, Sodium-Glucose Cotransporter 2 Inhibitors, Pioglitazone, Molecular Mechanisms of Pharmacological Action, Empagliflozin, Thiazolidinediones
06/22
06/22
ENVELOP, NCT06642623: A Prospective Trial of Enavogliflozin to Evaluate Cardio-renal Outcome in Type 2 Diabetes Mellitus Patients

Recruiting
4
2862
RoW
Enavogliflozin, Dapagliflozin or Empagliflozin
Yonsei University
Diabetes Mellitus, Type 2, Cardiovascular Diseases, Kidney Diseases
09/29
12/30
Lee, Yong-ho
ENAVO-AF, NCT06528262: Effect of Enavogliflozin on Recurrence of Atrial Fibrillation After Catheter Ablation

Not yet recruiting
4
390
RoW
Enavogliflozin, Placebo
Yonsei University
Atrial Fibrillation
08/26
08/26
NCT05975528: Effect of Sodium-glucose Cotransporter-2 Inhibitor in Cellular Senescence in Patients With Cardiovascular Diseases or Type 2 Diabetes

Recruiting
4
92
RoW
SGLT2 inhibitor, Glimepiride
Yonsei University
Diabetes Mellitus, Cellular Senescence, Sodium-Glucose Transporter 2 Inhibitors
12/25
12/25
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2749
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
09/25
01/26
TRIUMPH-2, NCT05929079: A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

Active, not recruiting
3
1000
Europe, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea
05/26
05/26
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
NCT06712615: Phase II Study of PG-102(MG12) Compared with Placebo in Obesity and Type 2 Diabetes

Recruiting
2
144
RoW
PG-102, Placebo
ProGen. Co., Ltd.
Type 2 Diabetes Mellitus (T2DM), Obesity Type 2 Diabetes Mellitus
03/25
06/25

Download Options